We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

54 hedge funds and large institutions have $12.8M invested in Cue Biopharma in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

488% more call options, than puts

Call options by funds: $47K | Put options by funds: $8K

260% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 5

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

22% more capital invested

Capital invested by funds: $10.5M → $12.8M (+$2.28M)

8% more funds holding

Funds holding: 50 → 54 (+4)

0.33% less ownership

Funds ownership: 0.95% → 0.62% (-0.33%)

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
18
Reduced
5
Closed
7
Calls
$47K
Puts
$8K
Net Calls
+$39K
Net Calls Change
+$23K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$153K
2
Bank of America
Bank of America
North Carolina
+$107K
3
Northern Trust
Northern Trust
Illinois
+$87.6K
4
BlackRock
BlackRock
New York
+$85.1K
5
HF
HRT Financial
New York
+$61.4K

Top Sellers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
-$1.82M
2
Millennium Management
Millennium Management
New York
-$363K
3
GCP
GSA Capital Partners
United Kingdom
-$178K
4
UBS Group
UBS Group
Switzerland
-$19.9K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$18.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cambridge Investment Research Advisors
26
Cambridge Investment Research Advisors
Iowa
$22K – – –
Wells Fargo
27
Wells Fargo
California
$21.9K – – –
Squarepoint
28
Squarepoint
New York
$21.5K +$24.7K +656 New
VF
29
Virtu Financial
New York
$18K +$21.1K +561 New
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$14.5K +$16.6K +442 New
SWM
31
SeaCrest Wealth Management
New York
$14.2K – – –
TRCT
32
Tower Research Capital (TRC)
New York
$11.5K +$4.13K +110 +46%
BPA
33
Beacon Pointe Advisors
California
$10.9K – – –
Simplex Trading
34
Simplex Trading
Illinois
$7K +$3.57K +95 +70%
Barclays
35
Barclays
United Kingdom
$6.57K – – –
GG
36
Gleason Group
Kentucky
$6.54K – – –
CSS
37
Cubist Systematic Strategies
Connecticut
$3.99K +$4.58K +122 New
NFSG
38
Newbridge Financial Services Group
Florida
$3.27K – – –
NA
39
NewEdge Advisors
Louisiana
$2.78K – – –
Northwestern Mutual Wealth Management
40
Northwestern Mutual Wealth Management
Wisconsin
$2.73K – – –
GSWM
41
Golden State Wealth Management
California
$2.18K +$2.52K +67 New
LFG
42
Larson Financial Group
Missouri
$1.53K – – –
JP Morgan Chase
43
JP Morgan Chase
New York
$1.16K +$188 +5 +17%
PWA
44
Physician Wealth Advisors
Utah
$1.1K +$1.28K +34 New
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$931 +$38 +1 +4%
Osaic Holdings
46
Osaic Holdings
Arizona
$414 – – –
MCM
47
MAI Capital Management
Ohio
$382 +$451 +12 New
SS
48
Sunbelt Securities
Texas
$242 – – –
AAG
49
Armstrong Advisory Group
Massachusetts
$131 – – –
IA
50
IFP Advisors
Florida
$109 – – –
1
2
3

CUE Hedge Fund Activity: Q4 2024 in Review

54 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2024, worth a combined $12.8M — up 22% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 7 closed out — a net gain of 4 holders — while 18 added to existing stakes and 5 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $153K. The largest seller was Slate Path Capital, exiting entirely with an estimated $1.82M sold.

  • 54 institutional investors held Cue Biopharma (CUE) as of Q4 2024, up from 50 in Q3 2024.
  • Funds reported $12.8M of Cue Biopharma stock for Q4 2024, up 22% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q4 2024 and 7 closed out, a net change of +4 holders.
  • The largest Cue Biopharma buyer in Q4 2024 was Geode Capital Management, an estimated $153K added.
  • The largest Cue Biopharma seller in Q4 2024 was Slate Path Capital, an estimated $1.82M sold.

Based on aggregated 13F filings for Q4 2024.